Downregulation of APRIN expression increases cancer cell proliferation via an interleukin-6/STAT3/cyclin D axis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sohn, Min-Shik | - |
dc.contributor.author | Kang, Miae | - |
dc.contributor.author | Kang, Seong-Man | - |
dc.contributor.author | Bae, Sangwoo | - |
dc.date.accessioned | 2021-08-30T04:35:31Z | - |
dc.date.available | 2021-08-30T04:35:31Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2021-01 | - |
dc.identifier.issn | 1792-1074 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/50232 | - |
dc.description.abstract | APRIN is a putative tumor suppressor whose expression is low in a variety of cancer cells. While decreased expression of APRIN leads to increased cell proliferation, unfavorable diagnosis or metastases in various cancer types, there is limited knowledge on the cellular mechanism of APRIN in cellular responses. The effect of APRIN depletion on cancer cell proliferation was examined in the present study, and the IL-6/STAT3/cyclin D axis was identified as a novel regulatory mechanism. Stable depletion of APRIN in cancer cells resulted in increased cell proliferation. Cytokine array analysis of the cells revealed that downregulation of APRIN induced secretion of interleukin-6 (IL-6) with corresponding activation of STAT3, a downstream intracellular mediator. Levels of cyclin D1 were increased in cells with APRIN depletion and cyclin D1 expression was associated with increased STAT3 binding on cyclin D1 promoter sequence; assessed by chromatin immunoprecipitation assay. The addition of an IL-6 neutralizing antibody P620 to the cell culture attenuated STAT3 activation and cyclin D1 expression in APRIN-depleted cells with corresponding decrease in cell proliferation. These experiments suggest that APRIN regulates cancer cell proliferation via an IL-6/STAT3/cyclin D axis and that targeting this axis in APRIN-associated cancer might provide a novel therapeutic approach. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPANDIDOS PUBL LTD | - |
dc.subject | NF-KAPPA-B | - |
dc.subject | ALLELIC LOSS | - |
dc.subject | CIRCULATING INTERLEUKIN-6 | - |
dc.subject | PROTEIN | - |
dc.subject | BRCA2 | - |
dc.subject | AS3 | - |
dc.subject | MARKER | - |
dc.subject | LOCUS | - |
dc.subject | GENE | - |
dc.subject | IL-6 | - |
dc.title | Downregulation of APRIN expression increases cancer cell proliferation via an interleukin-6/STAT3/cyclin D axis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kang, Seong-Man | - |
dc.identifier.doi | 10.3892/ol.2020.12317 | - |
dc.identifier.scopusid | 2-s2.0-85096656167 | - |
dc.identifier.wosid | 000599837500001 | - |
dc.identifier.bibliographicCitation | ONCOLOGY LETTERS, v.21, no.1 | - |
dc.relation.isPartOf | ONCOLOGY LETTERS | - |
dc.citation.title | ONCOLOGY LETTERS | - |
dc.citation.volume | 21 | - |
dc.citation.number | 1 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | NF-KAPPA-B | - |
dc.subject.keywordPlus | ALLELIC LOSS | - |
dc.subject.keywordPlus | CIRCULATING INTERLEUKIN-6 | - |
dc.subject.keywordPlus | PROTEIN | - |
dc.subject.keywordPlus | BRCA2 | - |
dc.subject.keywordPlus | AS3 | - |
dc.subject.keywordPlus | MARKER | - |
dc.subject.keywordPlus | LOCUS | - |
dc.subject.keywordPlus | GENE | - |
dc.subject.keywordPlus | IL-6 | - |
dc.subject.keywordAuthor | APRIN (PDS5B) | - |
dc.subject.keywordAuthor | interleukin-6 | - |
dc.subject.keywordAuthor | STAT3 | - |
dc.subject.keywordAuthor | cyclin D1 | - |
dc.subject.keywordAuthor | cancer cell proliferation | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.